| Literature DB >> 23776548 |
Xueling Sim1, Richard A Jensen, M Kamran Ikram, Mary Frances Cotch, Xiaohui Li, Stuart MacGregor, Jing Xie, Albert Vernon Smith, Eric Boerwinkle, Paul Mitchell, Ronald Klein, Barbara E K Klein, Nicole L Glazer, Thomas Lumley, Barbara McKnight, Bruce M Psaty, Paulus T V M de Jong, Albert Hofman, Fernando Rivadeneira, Andre G Uitterlinden, Cornelia M van Duijn, Thor Aspelund, Gudny Eiriksdottir, Tamara B Harris, Fridbert Jonasson, Lenore J Launer, John Attia, Paul N Baird, Stephen Harrap, Elizabeth G Holliday, Michael Inouye, Elena Rochtchina, Rodney J Scott, Ananth Viswanathan, Guo Li, Nicholas L Smith, Kerri L Wiggins, Jane Z Kuo, Kent D Taylor, Alex W Hewitt, Nicholas G Martin, Grant W Montgomery, Cong Sun, Terri L Young, David A Mackey, Natalie R van Zuydam, Alex S F Doney, Colin N A Palmer, Andrew D Morris, Jerome I Rotter, E Shyong Tai, Vilmundur Gudnason, Johannes R Vingerling, David S Siscovick, Jie Jin Wang, Tien Y Wong.
Abstract
Narrow arterioles in the retina have been shown to predict hypertension as well as other vascular diseases, likely through an increase in the peripheral resistance of the microcirculatory flow. In this study, we performed a genome-wide association study in 18,722 unrelated individuals of European ancestry from the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium and the Blue Mountain Eye Study, to identify genetic determinants associated with variations in retinal arteriolar caliber. Retinal vascular calibers were measured on digitized retinal photographs using a standardized protocol. One variant (rs2194025 on chromosome 5q14 near the myocyte enhancer factor 2C MEF2C gene) was associated with retinal arteriolar caliber in the meta-analysis of the discovery cohorts at genome-wide significance of P-value <5×10(-8). This variant was replicated in an additional 3,939 individuals of European ancestry from the Australian Twins Study and Multi-Ethnic Study of Atherosclerosis (rs2194025, P-value = 2.11×10(-12) in combined meta-analysis of discovery and replication cohorts). In independent studies of modest sample sizes, no significant association was found between this variant and clinical outcomes including coronary artery disease, stroke, myocardial infarction or hypertension. In conclusion, we found one novel loci which underlie genetic variation in microvasculature which may be relevant to vascular disease. The relevance of these findings to clinical outcomes remains to be determined.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23776548 PMCID: PMC3680438 DOI: 10.1371/journal.pone.0065804
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of the discovery and replication cohorts.
| Discovery cohorts | Replication cohorts | ||||||
| AGES | ARIC | CHS | RS | BMES | Australian Twins | MESA | |
| N | 2,949 | 7,260 | 1,263 | 4,820 | 2,430 | 1,769 | 2,170 |
| Age (years) | 76.2 (5.4) | 59.9 (5.6) | 78.4 (4.2) | 68.0 (8.2) | 66.8 (9.0) | 22.0 (11.9) | 62.2 (10.0) |
| [66–94] | [50–71] | [72–95] | [55–99] | [49–96] | [5–90] | [44–84] | |
| Proportion female (%) | 57.5 | 53.5 | 63.0 | 59.0 | 56.9 | 56.0 | 49.0 |
| CRAE (µm) | 139.7 (13.4) | 135.1 (12.8) | 138.8 (14.2) | 150.0 (14.4) | 160.0 (15.4) | 164.3 (13.6) | 142.7 (14.3) |
| [74.0–221.4] | [72.6–187.2] | [77.6–191.0] | [98.5–235.4] | [91.4, 210.7] | [83.6–205.2] | [83.3–219.2] | |
| CRVE (µm) | 202.0 (19.5) | 199.5 (19.1) | 196.5 (19.2) | 226.0 (20.1) | 224.6 (20.2) | 248.0 (19.0) | 206.5 (21.1) |
| [123.8–273.0] | [129.3–304.1] | [142.5–271.7] | [162.5–324.3] | [150.0–311.7] | [130.5–325.7] | [123.6–289.9] | |
| Body mass index (kg/m2) | 27.1 (4.4) | 28.0 (5.2) | 26.8 (4.3) | 26.3 (3.7) | 27.6 (4.7) | NA | 27.7 (5.0) |
| [14.8–48.5] | [14.2–59.1] | [15.6–46.7] | [14.2–50.7] | [16.5–49.2] | [16.9–49.0] | ||
| Systolic blood pressure (mmHg) | 142.5 (20.2) | 122.4 (18.0) | 134.3 (20.4) | 138.5 (22.1) | 146.0 (21.4) | NA | 122.6 (19.9) |
| [92.0–253.0] | [63.0–226.0] | [82.0–241.0] | [74.0–250.0] | [90.0–235.0] | [75.0–208.5] | ||
| Diastolic blood pressure (mmHg) | 74.1 (20.2) | 70.74 (10.0) | 67.9 (10.8) | 73.7 (11.4) | 84.8 (10.2) | NA | 70.1 (9.9) |
| [92.0–253.0] | [32.0–114.0] | [15.0–110.0] | [24.0–139.0] | [50.0–120.0] | [41.0–108.0] | ||
| Hypertension (%) | 80.6 | 39.3 | 48.8 | 42.3 | 50.9 | 3.2 | 37.5 |
| Diabetes mellitus (%) | 11.4 | 11.9 | 12.3 | 10.0 | 10.3 | 1.0 | 5.4 |
| Current smoker (%) | 12.5 | 17.3 | 6.1 | 23.6 | 9.8 | 11.0 | 11.2 |
AGES: Age Gene/Environment Susceptibility – Reykjavik Study, ARIC: Atherosclerosis Risk in Communities Study, CHS: Cardiovascular Health Study, RS: Rotterdam Study, BMES: Blue Mountains Eye Study. MESA: Multi-Ethnic Study of Atherosclerosis. Mean (standard deviation) [range] are given for continuous variables. Percentages are given for categorical variables.
Figure 1A) QQ-plot of –log10(observed P-values) against –log10(expected P-values) and B) Manhattan plot of –log10 transformed P-values of retinal arteriolar caliber against their physical position.
Figure 2Regional association plots at the two loci that exhibit genome-wide significance at discovery stage and one locus that showed suggestive evidence of association at P-value <10−6.
A) Chromosome 5 near TMEM161B and MEF2C, B) Chromosome 17 on SFRS2 and C) Chromosome 13 on FLT. In each regional plot, the index SNP is represented by a purple circle for the meta-analysis of the five discovery studies and a purple diamond for meta-analysis of discovery and replication studies. The remaining SNPs are colour coded according to pairwise linkage disequilibrium (LD) with the index SNP on a scale of r2 from 0 (blue) to 1 (red). Estimated recombination rates reflect the local LD structure in the 500 kb buffer around the index SNP and plotted based on values on Hapmap II CEU. Data for gene annotations are obtained from the RefSeq track of the UCSC Gene Browser (See LocusZoom http://csg.sph.umich.edu/locuszoom/ more details).
Association of index SNP with retinal arteriolar caliber at three top loci for each discovery cohort and meta-analysis.
| SNP (chr: position) | Ref/Effective allele (+) | Cohort | Eff allele freq (G/I) | Beta (SE) |
| Genes of interest | # SNPs |
| rs2194025 (5: 87833992) | C/G | AGES | 0.95 (I: 0.95) | −1.32 (0.80) | 1.01×10−1 |
| 31 |
| ARIC | 0.90 (I: 0.99) | −1.28 (0.37) | 4.83×10−4 |
| |||
| CHS | 0.91 (I: 0.96) | −3.20 (1.11) | 3.70×10−3 | ||||
| RS | 0.90 (I: 0.99) | −1.40 (0.49) | 4.15×10−3 | ||||
| BMES | 0.90 (I: 0.99) | −2.90 (0.73) | 6.69×10−5 | ||||
|
|
|
|
| ||||
|
|
|
|
|
|
| ||
| rs3744061 (17: 72244998) | A/G | AGES | 0.46 (I: 0.92) | −0.95 (0.36) | 7.89×10−3 |
| 4 |
| ARIC | 0.44 (I: 0.95) | −1.04 (0.22) | 2.31×10−6 |
| |||
| CHS | 0.43 (I: 0.88) | −1.15 (0.63) | 6.89×10−2 |
| |||
| RS | 0.42 (I: 0.95) | −0.29 (0.31) | 3.48×10−1 |
| |||
| BMES | 0.45 (I: 0.95) | −0.63 (0.45) | 1.55×10−1 | ||||
|
|
|
|
| ||||
|
|
|
|
|
|
| ||
| rs2281827 (13: 27899721) | T/C | AGES | 0.78 (I: 0.89) | −1.27 (0.45) | 4.96×10−3 |
| 2 |
| ARIC | 0.77 (I: 0.92) | −0.42 (0.26) | 1.09×10−1 | ||||
| CHS | 0.73 (I: 0.81) | −1.04 (0.68) | 1.26×10−1 | ||||
| RS | 0.78 (I: 0.88) | −1.63 (0.38) | 1.66×10−5 | ||||
| BMES | 0.76 (I: 0.89) | −0.84 (0.54) | 1.22×10−1 | ||||
|
|
|
|
|
AGES: Age Gene/Environment Susceptibility – Reykjavik Study, ARIC: Atherosclerosis Risk in Communities Study, CHS: Cardiovascular Health Study, RS: Rotterdam Study, BMES: Blue Mountains Eye Study.
The allele that decreases retinal arteriolar caliber is presented as the effective allele.
(G/I): Indicates if the SNP is directly genotyped (G) or imputed (I). If the SNP is imputed, the imputation quality is included.
Results for retinal arteriolar caliber for discovery cohort meta-analysis and replication cohorts.
| SNP (chr: position) | Ref/Effectiveallele (+) | Cohort | Eff allelefreq | Beta (SE) |
| Genes of interest |
| rs2194025 (5: 87833992) | C/G | Discovery cohorts combined | 0.91 | −1.60 (0.25) | 1.53×10−10 |
|
| MESA Whites | 0.91 | −2.03 (0.76) | 7.00×10−3 |
| ||
| Australian Twins | 0.91 | −1.14 (0.83) | 1.68×10−1 | |||
| Replication cohorts combined | 0.91 | −1.62 (0.56) | 3.74×10−3 | |||
|
|
| − |
| |||
|
|
|
|
|
| ||
| rs3744061 (17: 72244998) | A/G | Discovery cohorts combined | 0.44 | −0.82 (0.15) | 2.49×10−8 |
|
| MESA Whites | 0.44 | −0.44 (0.45) | 3.20×10−1 |
| ||
| Australian Twins | 0.45 | −1.75 (0.49) | 3.01×10−4 |
| ||
| Replication cohorts combined | 0.45 | −1.04 (0.33) | 1.51×10−3 |
| ||
|
|
| − |
| |||
|
|
|
|
|
| ||
| rs2281827 (13: 27899721) | T/C | Discovery cohorts combined | 0.77 | −0.90 (0.18) | 3.55×10−7 |
|
| MESA Whites | 0.75 | −0.15 (0.51) | 7.70×10−1 | |||
| Australian Twins | 0.76 | 0.74 (0.57) | 1.92×10−1 | |||
| Replication cohorts combined | 0.75 | 0.25 (0.38) | 5.12×10−1 | |||
|
|
| − |
|
SE: standard error, OR: odds ratio, MESA: Multi-Ethnic Study of Atherosclerosis.
The allele that decreases retinal arteriolar caliber is presented as the effective allele (refer to Table 2).
Figure 3Regional association plots for retinal arteriolar caliber conditioned on retinal venular caliber for A) Chromosome 5 near TMEM161B and MEF2C and B) Chromosome 17 on SFRS2.
All regional plots are centered on the index SNPs, with a 500 kb buffer on both sides of the index SNP.
Figure 4Regional association plot at chromosome 5 locus using ARIC data, showing P-values for SNPs for retinal arteriolar caliber (CRAE), retinal venular caliber (CRVE), retinal arteriolar caliber conditioned on CRAE index SNP rs2194025 and retinal arteriolar caliber conditioned on CRVE implicated SNP rs17421627.
Association of the three index SNPs with macrovascular diseases.
| SNP (chr: position) | Ref/Effective allele (+) | Cohort | Eff allele freq | OR (95% CI) |
|
| rs2194025 (5: 87833992) | C/G | WTCCC (CAD) 2,000 cases/3,000 controls | 0.91 | 1.00 (0.86–1.15) | 0.96 |
| HVH (Stroke) 501 cases/1,314 controls | 0.91 | 0.91 (0.69–1.19) | 0.50 | ||
| HVH (MI) 1,172 cases/1,314 controls | 0.91 | 1.01 (0.83–1.24) | 0.91 | ||
| Global BPGen (HTN) ∼9,000 case control pairs | 0.90 | 0.95 (0.87–1.03) | 0.21 | ||
| GoDARTS (CAD) 541 cases/2,058 controls | 0.91 | 1.13 (0.84–1.53) | 0.39 | ||
| GoDARTS (Incident CAD) | 0.91 | 1.00 (0.70–1.42) | 0.99 | ||
| GoDARTS (Incident Ischaemic Stroke) | 0.91 | 1.06 (0.69–1.64) | 0.79 | ||
|
|
|
|
| ||
| rs3744061 (17: 72244998) | A/G | WTCCC (CAD) 2,000 cases/3,000 controls | 0.45 | 1.05 (0.97–1.15) | 0.21 |
| HVH (Stroke) 501 cases/1,314 controls | 0.43 | 0.96 (0.82–1.13) | 0.62 | ||
| HVH (MI) 1,172 cases/1,314 controls | 0.44 | 1.07 (0.95–1.21) | 0.26 | ||
| Global BPGen (HTN) ∼9,000 case control pairs | 0.47 | 1.02 (0.97–1.07) | 0.42 | ||
| GoDARTS (CAD) 541 cases/2,058 controls | 0.41 | 0.92 (0.78–1.11) | 0.39 | ||
| GoDARTS (Incident CAD) | 0.41 | 0.96 (0.83–1.29) | 0.75 | ||
| GoDARTS (Incident Ischaemic Stroke) | 0.42 | 0.93 (0.71–1.23) | 0.62 | ||
|
|
|
|
| ||
| rs2281827 (13: 27899721) | T/C | WTCCC (CAD) 2,000 cases/3,000 controls | 0.77 | 1.07 (0.97–1.19) | 0.18 |
| HVH (Stroke) 501 cases/1,314 controls | 0.75 | 0.96 (0.78–1.18) | 0.70 | ||
| HVH (MI) 1,172 cases/1,314 controls | 0.75 | 0.99 (0.85–1.15) | 0.87 | ||
| Global BPGen (HTN) ∼9,000 case control pairs | 0.78 | 1.01 (0.95–1.07) | 0.86 | ||
| GoDARTS (CAD) 541 cases/2,058 controls | 0.77 | 1.23 (1.01–1.50) | 0.04 | ||
| GoDARTS (Incident CAD) | 0.77 | 1.22 (0.94–1.59) | 0.14 | ||
| GoDARTS (Incident Ischaemic Stroke) | 0.77 | 0.56 (0.42–0.75) | 1.14×10−4 |
SE: standard error, OR: odds ratio, N: number of incident events, HR: hazards ratio, WTCCC: Wellcome Trust Case Control Consortium, CAD: Coronary Artery Disease, HVH: Heart and Vascular Health Study, MI: Myocardial infarction, Global BPGen: Global Blood Pressure Genetics Consortium; HTN: hypertension, GoDARTS: Genetics of Diabetes Audit and Reseach Tayside Scotland.
The allele that decreases retinal arteriolar caliber is presented as the effective allele (refer to Table 2).
excludes cardioembolic stroke.
adjusted for age, gender, BMI, history of smoking and hypertension medication.
adjusted for age, gender, BMI, history of smoking, previous CAD events and previous ischaemic stroke events.